- Login
- Register & Subscribe
- Sprache: EN FR DE
Finance, Grants, Deals
Pieris receives €1 million grant for cancer project
Tuesday 7 February 2012
Venture-capital backed Pieris AG has received a €1 million German government grant to support the development of a cancer compound that targets the c-Met signalling pathway. The funds will be used for biomarker discovery.
Location
Germany
Cytos bond restructuring approved by Swiss court
Monday 6 February 2012
Cytos Biotechnology Ltd has received approval from a court in the canton of Zurich to restructure a convertible bond valued at about $44.8 million. This follows a move to cut its workforce last August from 82 to10 and to reduce the size of its executive.
Location
Switzerland
Wilex to receive €2.6 million for cancer compound
Monday 6 February 2012
Wilex AG is set to receive up to €2.6 million from the German government to support the preclinical and clinical development of a small molecule cancer compound that targets the P13K signalling pathway.
Location
Germany
Targovax funds pancreatic cancer vaccine
Thursday 2 February 2012
A Norwegian start-up company,Targovax AS, has raised NOK 13 million (€1.7 million) in a Series A financing round to support the clinical development of a therapeutic vaccine against pancreatic cancer. The candidate product is a peptide vaccine that targets mutations on ras genes.
Location
Norway
Wilex successfully completes rights offering
Wednesday 1 February 2012
Wilex AG, which has an antibody treatment for renal cell cancer in a pivotal Stage 3 trial along with a companion diagnostic, has successfully completed a €9.93 million rights issue. Wilex is based in Munich, Germany.
Location
Germany
Domain Therapeutics receives grant for PD
Tuesday 31 January 2012
Venture-capital backed Domain Therapeutics SA of France has received a grant from the Michael J. Fox Foundation to develop allosteric modulators for Parkinson’s disease. This follows a year-earlier licensing deal with Merck Serono, also for PD.
Location
France
Amgen to buy Micromet for $1.16 billion
Thursday 26 January 2012
Amgen Inc has agreed to pay $1.16 billion in cash to acquire Micromet Inc, a developer of bispecific antibodies. Micromet’s key asset is blinatumomab, an antibody in early clinical development against acute lymphoblastic leukaemia.
Location
United States
Celgene to acquire Avila Therapeutics
Thursday 26 January 2012
Celgene Corp said it has reached agreement to acquire venture-capital backed Avila Therapeutics Inc for $350 million in cash, plus milestones, thereby strengthening its position in the area of haematologic cancers.
Location
United States
CN Creative raises £2 million in Series A
Thursday 26 January 2012
A UK start-up, CN Creative Ltd, which has developed an electronic smoking cessation device, has raised £2 million in a Series A round led by Advent Life Sciences. The money will support final development of its novel inhaler product.
Location
United Kingdom
Roche makes hostile bid for Illumina
Wednesday 25 January 2012
The Roche group has stepped up its commitment to personalised medicine with the announcement of a hostile $5.7 billion bid for Illumina Inc of the US, a leading provider of molecular diagnostics. The all-cash offer values each share at $44.50.
Location
Switzerland
Select a News Category
Recent Appointments
Rajesh Chopra joins e-Therapeutics’s Board of Directors
Tuesday February 7 2012
Carolyn Compton named CEO of Critical Path Institute
Friday February 3 2012
John Perkins appointed UK chief scientific advisor
Monday January 23 2012
Briggs Morrison to lead global medicines development at AstraZeneca
Wednesday January 11 2012
Russell Greig appointed chair of AM-Pharma supervisory board
Wednesday January 4 2012